Gene and Cell Therapies Targeting CNS Disorders Market

The global Gene and Cell Therapies Targeting CNS Disorders market was valued at USD 7.9 Bn in 2026 and is expected to reach USD 24.0 Bn by 2033, growing at a CAGR of 16.5% from 2026 to 2033. The market is at a transformational phase now, wherein the breakthroughs in molecular biology, genetics, and regenerative medicine are rewriting the treatment paradigms for CNS disorders. Traditionally, CNS diseases were managed by symptomatic treatments due to the intricacies in the brain and spinal cord along with the presence of the blood–brain barrier. Gene and cell therapies, however, can now circumvent such difficulties and allow targeted, disease-modifying, and potentially curative interventions. Gene and cell therapies targeting CNS disorders cover a wide range of sophisticated therapeutic modalities, including viral vector-based gene replacement; gene silencing and editing technologies, including CRISPR; induced pluripotent stem cell-derived neural progenitors; and a variety of stem cell transplantation approaches. These therapies aim at correcting genetic defects, restoring neuronal function, replacing damaged cells, or modulating disease pathways at a molecular level. Neurogenetics and neurobiology have ignited and accelerated innovation in this field to date, making CNS disorders a viable and increasingly attractive therapeutic area. The increasing incidence of neurodegenerative and neurological disorders such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis is a significant factor contributing to the growth of the market. With the rising geriatric population, advancements in diagnostic technologies, and greater awareness, the incidence of diseases is on a rise. Market Dynamics The market for gene and cell therapies targeting CNS disorders has been gaining significant traction due to the increasing prevalence of neurodegenerative diseases and the urgent unmet need for disease-modifying treatments. Such diseases as Parkinson's disease and Alzheimer's continue to increase in incidence throughout the world, placing a significant burden on the global health care system. This, in turn, increases the need for cutting-edge treatment solutions targeting the root cause of diseases instead of just relieving symptoms. Technological advancements, another major driving factor which is anticipated to have a significant future impact on the development of the market is technological advancements. Advances in the technology area for viral vectors, ranging from adeno-associated virus (AAV) to lentiviral vectors, have resulted in enhanced delivery efficacy and safety associated with the vectors to the CNS. Similarly, advances in the area of stem cell research have resulted in the development of stem cells that are scalable and well-characterized from a functional perspective for transplantation purposes in the CNS. The regulatory landscape is also evolving in favor of market expansion. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly offering accelerated approval pathways, orphan drug designations, and regulatory guidance specifically tailored to advanced therapy medicinal products (ATMPs). These initiatives reduce development timelines and provide greater clarity for manufacturers, thereby encouraging investment and innovation in the CNS gene and cell therapy space. Moreover, the incorporation of artificial intelligence and digital health technologies into CNS therapeutic development is improving the efficiency and rates of clinical trials. The use of machine learning approaches to stratify patients, digital biomarkers, and real-time disease monitoring solutions are allowing for more focused trials, measurement of endpoints, and post-market surveillance. This is significant, as it is in the realm of CNS disorders, where the complexity and slowing rate of progression have traditionally clouded clinical assessment. Key Features of the Study • This report provides in-depth analysis of the Gene and Cell Therapies Targeting CNS Disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year. • It elucidates potential revenue opportunities across different segments such as therapy type, indication, and geography, and explains attractive investment proposition matrices for this market. • This study provides key insights about market drivers, restraints, opportunities, technological breakthroughs, regulatory developments, advanced-stage clinical trials, market trends, regional outlook, and competitive strategies adopted by key players. • It profiles key players in the gene and cell therapies targeting CNS disorders market based on the following parameters – company overview, therapeutic pipeline, technology platforms, key developments, and strategic initiatives. • Key companies covered as part of this study include Novartis, BrainStorm Cell Therapeutics, Corestem, Q Therapeutics, Helixmith, Rapa Therapeutics, Neuroplast, StemCyte, Ferrer Internacional, Neuralstem, Stemedica Cell Technologies, Libella Gene Therapeutics, Sangamo Therapeutics, Hoffmann-La Roche, LSio Gene Therapies, Eli Lilly and Company, NeuroGeneration, Brain Neurotherapy Bio (AskBio), and uniQure Biopharma • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The Gene and Cell Therapies Targeting CNS Disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Gene and Cell Therapies Targeting CNS Disorders Market Market Segmentation • Therapy Type Insights (Revenue, USD Bn, 2026 - 2033) o Gene Therapy o Cell Therapy • Indication Insights (Revenue, USD Bn, 2026 - 2033) o Alzheimer's Disease (AD) o Huntington's Disease (HD) o Parkinson's Disease (PD) o Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease o Multiple Sclerosis (MS) o Adrenoleukodystrophy & Metachromatic Leukodystrophy o Neuropathies o Batten Disease (BD) • Regional Insights (Revenue, USD Bn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Novartis o BrainStorm Cell Therapeutics o Corestem o Q Therapeutics o Helixmith o Rapa Therapeutics o Neuroplast o StemCyte o Ferrer Internacional o Neuralstem o Stemedica Cell Technologies o Libella Gene Therapeutics o Sangamo Therapeutics o Hoffmann-La Roche o LSio Gene Therapies o Eli Lilly and Company o NeuroGeneration o Brain Neurotherapy Bio (AskBio) o UniQure Biopharma